News

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine VANCOUVER, June 07, 2022 (GLOBE…

2 years ago

Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001

NEWTON, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,…

2 years ago

SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.

SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addictionTEL AVIV, Israel, June 07,…

2 years ago

Simply Better Brands Corp and Jones Soda Co. Announce Termination of Letter of Intent Due to Unfavourable Market Conditions

VANCOUVER, British Columbia, June 07, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ( “Simply Better Brands” or “SBBC”) (TSX…

2 years ago

Pharvaris Participates in the Kinin 2022 Conference

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at…

2 years ago

Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…

2 years ago

Ceapro Announces Results of 2022 Shareholders’ Meeting

EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage…

2 years ago

Eyenovia Announces Planned Chief Executive Officer Transition

CEO Dr. Sean Ianchulev will transition to non-executive Chairman of the BoardNEW YORK, June 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia,…

2 years ago

Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update

Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q…

2 years ago

ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia

Non-refundable funds from the Next Generation-EU programMADRID, Spain and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A.…

2 years ago